| |
|
|
|
Xtalks, Online
2024-10-25
Biomarker-driven clinical trials are critical to advancing precision medicine, yet they often face significant challenges, including slow patient recruitment, complex logistics and high costs. Centralized next-generation sequencing (NGS) testing can exacerbate these issues, delaying the identification of eligible patients and hindering timely enrollment and treatment initiation.
Rapid and decentralized NGS technologies present a promising strategy for addressing these challenges, offering the potential to streamline clinical trials. Decentralized NGS enables testing capabilities closer to patients, reducing the reliance on central laboratories and minimizing the time required for sample transportation and processing.
Read more...
This approach allows for faster identification of relevant mutations and more efficient patient stratification, leading to improvement in recruitment rates and reduction in trial timelines. Decentralized NGS also enhances accessibility for patients in remote or underserved areas, helping to ensure more diverse and representative trial populations. The rapid turnaround time of advanced NGS platforms further accelerates trial workflows, enabling timely molecular data necessary to make informed decisions on patient treatment paths.
In this webinar, the speakers will discuss the transformative role of decentralized NGS in streamlining trial operations. By decentralized NGS testing, clinical trials can significantly reduce reliance on central laboratories, thus minimizing delays in sample transportation and processing and enabling faster identification of eligible patients.
This webinar will also cover the critical importance of timely genomic profiling in clinical trials. As the identification of relevant mutations can directly impact treatment decisions, the rapid turnaround time of an advanced NGS platform enables investigators with crucial information for timely and informed decisions.
Register for this webinar today to understand how decentralized NGS testing reduced reliance on minimizes time required for sample transportation and processing.
Keywords: Precision Medicine, Clinical Research, Oncology, Patient Recruitment, Biomarkers, Genomics, NGS, Clinical Data, Diagnostics, Therapeutic Areas, NGS Cancer Testing, NGS Sequencing, CT Logistics
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jane Li, Senior Director, Pharma and CRO, Life Sciences Solutions Group, Thermo Fisher Scientific
Dr. Binh Nguyen, VP, Medical Science and Strategy, Clinical Research, Thermo Fisher Scientific
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-25
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|